A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma

导出原文传递

翻译打印收藏纠错

作者： Ghobrial, Irene M. ^[1] ; Liu, Chia-Jen ^[2] ; Redd, Robert A. ^[3] ; Perez, Raymond P. ^[4] ; Baz, Rachid ^[5] ; Zavidij, Oksana ; Sklavenitis-Pistofidis, Romanos ; Richardson, Paul G. ; Anderson, Kenneth C. ; Laubach, Jacob ; Henrick, Patrick ; Savell, Alexandra ; Reyes, Kaitlen ; Hornburg, Kalvis ; Chuma, Stacey ; Sabbatini, Peter ; Robbins, Michael D. ; Becker, Pamela S.

作者单位： Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA ^[1] Bristol Myers Squibb, Sunnyvale, CA USA ^[2] Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA ^[3] Univ Washington, Seattle, WA 98195 USA ^[4] Univ Kansas, Fairway, KS USA ^[5]

发布时间 2020-10-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Clinical cancer research

2020年26卷2期

344-353页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

检索历史清除